News Search Results
Aug 14, 2025, 20:15 ET CARsgen Therapeutics Announces 2025 Interim Results
CARsgen's share in UCARsgen will be diluted from 100% to 92%. UCARsgen is a China-based new drug discovery biotechnology company focused on allogeneic CAR T-cell therapies for the treatment of hematologic malignancies. Under the Agreements, UCARsgen has secured the
More news about: CARsgen Therapeutics
Aug 14, 2025, 16:30 ET Essa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash Distribution
the business of the Company pursuant to the Company's previously announced transaction with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire all of the issued and outstanding Common Shares (the "Transaction"), the Nasdaq Stock Market LLC ("Nasdaq")
More news about: ESSA Pharma Inc.
Aug 14, 2025, 16:05 ET Tyra Biosciences Reports Second Quarter 2025 Financial Results and Highlights
Aug. 14, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Aug 14, 2025, 12:30 ET Biotech Stocks Rally as Oncology Market Targets $866B by 2034
ProPhase Labs, Inc. (NASDAQ: PRPH), IO Biotech, Inc. (NASDAQ: IOBT), Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), and PDS Biotechnology Corporation (NASDAQ: PDSB).
More news about: Equity Insider
Aug 14, 2025, 11:00 ET Enterprise Imaging IT Market worth US$4.12 Billion by 2030 with 12.2% CAGR | MarketsandMarkets™
cardiovascular information systems (CVIS), and practice applications. The main end users of the company's solutions include hospitals, pharmaceutical firms, biotechnology companies, medical facilities, and life science research bodies. GE HealthCare serves customers in over 160 countries, conducts R&D in 18 countries,
More news about: MarketsandMarkets
Aug 14, 2025, 10:01 ET Graphene Market to Register a CAGR of 24% by 2031 - Driven by Flourishing Electronics and Energy Storage Industry | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 14, 2025, 10:01 ET Home Healthcare Market is Estimated to Reach USD 539.58 Billion by 2032 | SkyQuest Technology Consulting
grow significantly due to the high prevalence of CVD. A study published in October 2024, by the Nation Center for Biotechnology Information (NCBI) found that cardiovascular disease (CVD) accounts for about 11% of all healthcare spending in the EU, making it a significant
More news about: SkyQuest Technology
Aug 14, 2025, 10:01 ET Public Cloud Infrastructure Managed Service Market Projected to Reach USD 120 Billion by 2033, Growing at a CAGR of 8.5% - Market Research Intellect
Medical Device Manufacturing, Laboratory Applications, Food and Beverage Processing, Cosmetic Production) and End-User (Pharmaceutical Companies, Biotechnology Companies, Contract Manufacturing Organizations, Research Laboratories, Healthcare Institutions) and geographical regions
More news about: Market Research Intellect
Aug 14, 2025, 09:20 ET Made Scientific and New Jersey Delegates Celebrate Grand Opening of Flagship Cell Therapy Manufacturing Facility
the global expertise and resources of GC Corporation of South Korea, a global leader in the pharmaceutical and biotechnology sectors.
More news about: Made Scientific, Inc.
Aug 14, 2025, 08:36 ET Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease
Nanoscope Therapeutics Inc., a biotechnology company committed to developing and commercializing novel gene-agnostic therapies for patients suffering vision loss from retinal degenerative diseases,
More news about: Nanoscope Therapeutics
Aug 14, 2025, 08:01 ET New RoviSys Office in Puerto Rico Strengthens Regional Support for Critical Industries
expansion positions RoviSys to better support clients in the region and enhance service delivery across key industries, including pharmaceuticals and biotechnology, food and beverage, power and energy, chemicals, and aerospace. The San Juan location was selected to provide
More news about: RoviSys
Aug 14, 2025, 07:30 ET Soligenix Announces Recent Accomplishments And Second Quarter 2025 Financial Results
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Aug 14, 2025, 07:00 ET Leap Therapeutics Reports Second Quarter 2025 Financial Results
Mass., Aug. 14, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today reported financial results for the second quarter of 2025. Leap
More news about: Leap Therapeutics, Inc.
Aug 14, 2025, 06:59 ET The Adtech market size was valued at US$828.60 billion in 2024 and is expected to reach US$1863.91 billion by 2031; at CAGR of 14.5% during 2025-2031 | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 14, 2025, 06:56 ET Infectious Disease Therapies Market Projected to Reach $101 Billion by End of 2030
for infectious diseases. Its intranasal vaccine candidate, CoviLiv, is a live-attenuated vaccine against COVID-19.nChroma Bio: A biotechnology company advancing genetic medicines. CRMA-1001 is an epigenetic editor in development as a potential treatment for chronic hepatitis B and hepatitis
More news about: BCC Research LLC
Aug 14, 2025, 05:24 ET Leads Biolabs Announces Completion of Patient Enrollment in Pivotal Trial of Opamtistomig Monotherapy for Extrapulmonary Neuroendocrine Carcinoma
the urgency to develop novel therapeutic approaches. About Leads Biolabs Founded in 2012, Leads Biolabs is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies to address underserved medical needs in oncology,
More news about: Leads Biolabs
Aug 13, 2025, 16:00 ET Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results
https://clinicaltrials.gov/study/ NCT06996080). About Kodiak Sciences Inc. Kodiak Sciences (Nasdaq: KOD) is a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics. We are focused on bringing new science to the design
More news about: Kodiak Sciences Inc.
Aug 13, 2025, 11:50 ET WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) ) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer has entered into securities purchase agreements with several
More news about: WallachBeth Capital LLC
Aug 13, 2025, 08:34 ET Chungnam National University Researchers Develop Next-Gen Zinc Batteries: Artificial Polymer Nanolayers Improve Zinc Battery Stability
university with a strong focus on research and education. Thanks to its location near the Daedeok Innopolis R&D hub, it excels in fields such as biotechnology, materials science, and information technology. About Associate Professor Woo-Jin Song Dr. Woo-Jin
More news about: Chungnam National University
Aug 13, 2025, 08:27 ET CIT Therapeutics Forms Strategic Partnership with the Institute for Follicular Lymphoma Innovation (IFLI), Securing Up to $2.5M to Advance Novel Cancer Therapies
Calif., Aug. 13, 2025 /PRNewswire/ -- CIT Therapeutics, Inc. (CIT), a biotechnology company focused on developing next-generation small molecule therapies targeting SUMOylation for cancer treatment, today announced a strategic partnership
More news about: Institute for Follicular Lymphoma Innovation (IFLI); CIT Therapeutics, Inc.
Aug 13, 2025, 08:05 ET TetraScience Launches Tetra Workflows to Automate Scientific Data Workflows at Scale
Modern laboratories are drowning in data management complexity. Scientists across pharmaceutical, biotechnology, and life sciences organizations waste up to 40% of their time on manual data movement between instruments, electronic lab notebooks (ELNs), laboratory
More news about: TetraScience
Aug 13, 2025, 08:00 ET Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners Advancing Central Nervous System Treatments
NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions announced several licensing deals with Galibra Neuroscience and Emugen Therapeutics to utilize
More news about: Apertura Gene Therapy
Aug 13, 2025, 08:00 ET BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
therapeutic fields, builds cutting-edge biotechnology platforms such as new protein, new antibody, nucleic acid drugs, and adheres to the platform driven development model of "innovation+internationalization", At the same time, it explores the extensive application of biotechnology in the field of general health,
More news about: BioDlink Biopharm Co., Ltd.
Aug 12, 2025, 19:57 ET CAPR Stock News: Investors with Large Losses Should Contact Robbins LLP to Learn About Leading the Capricor Therapeutics, Inc. Class Action Lawsuit
securities between October 9, 2024 and July 10, 2025. Capricor is a clinical-stage biotechnology company that engages in the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD) and
More news about: Robbins LLP
Aug 12, 2025, 19:00 ET Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model
including tirzepatide in future clinical trials." About Ascletis Pharma Inc. Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.